Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer
Our previous study demonstrated that administration of NVP-BEZ235 (BEZ235), a dual PI3K/mTOR inhibitor, before radiotherapy (RT) enhanced the radiotherapeutic effect in colorectal cancer (CRC) cells both in vitro and in vivo. Here, we evaluated whether maintenance BEZ235 treatment, after combinatori...
Main Authors: | Yu-Hsuan Chen, Chun-Wei Wang, Ming-Feng Wei, Yi-Shin Tzeng, Keng-Hsueh Lan, Ann-Lii Cheng, Sung-Hsin Kuo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/8/1204 |
Similar Items
-
The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma
by: Cheng-Chan Yu, et al.
Published: (2020-05-01) -
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens
by: Yi-Ying Wu, et al.
Published: (2019-07-01) -
Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis
by: Zou H, et al.
Published: (2016-05-01) -
Characterization of BK viral responses to the dual-PI3K/MTOR inhibitor dactolisib (NVP BEZ-235) in a renal cell culture model
by: Lerner, Gabriel B.
Published: (2016) -
A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia
by: Fabian Lang, et al.
Published: (2020-09-01)